Compare BIO-TECHNE Corp (TECH) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Advanced Drainage Systems Inc — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Advanced Drainage Systems Inc trades at $143.04 (market cap $10.96B). The key difference: BIO-TECHNE Corp and Advanced Drainage Systems Inc are close in size by market cap, and Advanced Drainage Systems Inc pays the higher dividend (0.56%). Which is the better fit depends on your goals.
| TECH | WMS | |
|---|---|---|
Market Cap | $11.16B | $10.96B |
Sector | Health | Industrials |
52-Week High | $72.12 | $175.38 |
52-Week Low | $43.31 | $110.99 |
Enterprise Value | $11.24B | $12.53B |
Dividend Yield | 0.45% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
WMS trades at $142.93, down 3.13% today, with a neutral technical signal and mixed analyst sentiment. The company shows strong profitability with a 13.98% net income margin and 24.02% ROE, though revenue remained flat at $2.90B in 2025. Recent earnings beats and a dividend increase signal management confidence, while cash flow turned negative due to increased investing activities.
The outlook is cautiously optimistic with a consensus price target of $184.43 offering 29% upside. Risks include volatile cash flows and competitive pressures, but consistent earnings outperformance and solid balance sheet strength support a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
